View the latest BOT/BAL presentation from ASCO

Our mission is to harness the power of the immune system to bring therapies with curative intent to individuals living with cancer

Latest News

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus’ Biologics Manufacturing in the US

$75M upfront payment to Agenus for the transfer of manufacturing assets
$50M of contingent payments to Agenus
Exclusive license for BOT/BAL in India and Sri Lanka
$16M equity investment at $7.50 per share

Recent Publications

Learn more about our latest:

Medical Congress Presentations
Conference Posters
Published Manuscripts

Agenus Medical Information

Here to answer your questions.

General Medical Information
Contact Request
Investigator Sponsored Clinical Trials
Access to Investigational Medicines

Spotlight on botensilimab

Agenus’ next-generation CTLA-4 antibody

Botensilimab was designed to:

Extend the curative benefits of I-O to cold tumors that do not respond to approved immunotherapies. This is achieved by optimizing T cell interactions to drive increased potency.
Expand clinical benefit in hot tumors such as melanoma, where CTLA-4 is approved, but reported results show clinical benefit in only a third of patients and long term survival in less than a quarter of patients.
Improve tolerability by reducing or eliminating side effects that cause treatment discontinuation.

Innovation in immunotherapy

What is immunotherapy for cancer?

Today, we can create drugs that empower the immune system to do its job – cure disease.

How does botensilimab work?

By modifying the Fc “tail” of the antibody, our scientists discovered that its efficacy and tolerability can be significantly enhanced.

By the numbers

Agenus discovers, manufactures, and develops immuno-oncology (I-O) therapeutics. Our vision is to expand the patient population benefiting from I-O through combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through subsidiary MiNK Therapeutics), adjuvants and vaccines (through subsidiary SaponiQx).

clinical-stage antibody programs

US patient opportunity for lead program

0 K

partnership transactions

$ 0 B

annual manufacturing capacity for botensilimab at planned Emeryville site

$ 0 B

Acceleration through partnerships

While we retain ownership in the majority of our programs, we have accelerated the development of select programs through partnerships with industry leaders. These partnerships generate capital to further support our pipeline development, and many offer optionality for future participation in development and commercialization.

Who we are

We have brought together top talent and expertise to advance our mission, building a team of employees across our offices in the US and Europe.